FDA approves pembrolizumab with chemotherapy for platinum-resistant ovarian cancer, showing significant survival benefits in ...

The FDA has cleared the investigational new drug (IND) application for NPX372, a first-in-class T-cell engager (TCE) for the ...

Usmani, MD, MBA, discussed the significance of phase 1 outcomes of gintemetostat therapy for patients with heavily pretreated ...

SEER-Medicare data show just 4% of older adults with blood cancers enter clinical trials, revealing disparities and fixable ...

The central finding was the superior activity of a 2-antibody combination against the type 1 mutant CALR neoantigen. Dual ...

Pellini notes that Hispanic patients often exhibit a higher incidence of specific genomic alterations in their cancers.

Like many cancers, acute myeloid leukemia (AML) has been a major beneficiary from the introduction of targeted therapies into the oncology treatment landscape. In fact, 1 of the earliest uses of ...

Rintatolimod (Ampligen) combined with durvalumab (Imfinzi) has continued to exhibit encouraging efficacy, safety, and ...

The FDA has granted priority review to the supplemental biologics license application for datopotamab deruxtecan (Dato-DXd) ...

Patients treated with ciltacabtagene autoleucel (cilta-cel; Carvykti) in the phase 3 CARTITUDE-4 trial (NCT04181827) achieved high rates of progression-free survival (PFS) at nearly 3 years, according ...

Community oncology plays a central role in the US health care system, offering high-quality care that is both accessible and ...

SEER-Medicare data show just 4% of older adults with blood cancers enter clinical trials, revealing disparities and fixable ...